Steroid receptor expression in endometria from women treated with tamoxifen

被引:18
作者
Kommoss, F [1 ]
Karck, U
Prompeler, H
Pfisterer, J
Kirkpatrick, CJ
机构
[1] Univ Mainz, Inst Pathol, D-55101 Mainz, Germany
[2] Univ Freiburg, Dept Obstet & Gynecol, D-79106 Freiburg, Germany
[3] Univ Kiel, Dept Obstet & Gynecol, D-24105 Kiel, Germany
关键词
D O I
10.1006/gyno.1998.5087
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer patients receiving tamoxifen (Tam) are at an increased risk for developing endometrial carcinomas, possibly due to the partial estrogenic effect of Tam on endometrial cells. Progestational therapy has not routinely been included in Tam regimens. It was our aim to determine the presence of estrogen receptors (ERs) and progesterone receptors (PRs) in normal and abnormal endometria from postmenopausal women with breast cancer who were treated with Tam. Standard immunohistochemical staining of ERs and PRs was performed on paraffin sections from formalin-fixed uterine curettings or hysterectomy specimens from 40 patients who had received 20-40 mg of Tam daily for a minimum of 3 months. For comparison, normal endometria from 20 women who had not received Tam (11 premenopausal, 9 postmenopausal) were also studied for ER and PR expression. Staining was evaluated using semiquantitative immunoreactivity scores (IRS) ranging from 0 (negative) to 12 (strongly positive). In the group of patients receiving Tam, ERs and PRs were detected in the nuclei of glandular cells in 24/24 cases of endometrial atrophy (ER/PR-IRS, 2-12), in 8/8 endometrial polyps (ER-IRS, 6-12; PR-IRS, 4-12), in 4/4 adenomatous endometrial hyperplasias (ER-IRS, 3-8; PR-IRS, 1-12), and in 4/4 well-differentiated endometrioid adenocarcinomas (ER-IRS, 2-12; PR-IRS, 6-8). Of the 11 endometria from premenopausal patients who had not received Tam, 8 were ER+/PR+ (ER-IRS, 1-12; PR-IRS, 1-12), 1 was ER+/PR- (ER-IRS, 3; PR-IRS, 0), 1 was ER-/PR+ (ER-IRS, 0; PR-IRS, 2), and 1 was ER-/PR- (ER/PR-IRS, 0). Among 9 atrophic endometria from women not treated with Tam, 6 were ER+/PR+ (ER-IRS, 4-12; PR-IRS, 3-6), 1 was ER+/PR- (ER-IRS, 4; PR-IRS, 0), and 2 were ER-/PR- (ER/PR-IRS, 0). The consistent finding of ER and PR expression in endometria from postmenopausal women receiving Tam further supports the suspected estrogenic effect exerted by Tam on endometrial cells. Progestational therapy could be beneficial in the prevention of Tam-induced abnormal endometrial proliferations. (C) 1998 Academic Press.
引用
收藏
页码:188 / 191
页数:4
相关论文
共 26 条
[1]   INCIDENCE OF NEW PRIMARY CANCERS AFTER ADJUVANT TAMOXIFEN THERAPY AND RADIOTHERAPY FOR EARLY BREAST-CANCER [J].
ANDERSSON, M ;
STORM, HH ;
MOURIDSEN, HT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (14) :1013-1017
[2]  
ANZAI Y, 1989, CANCER RES, V49, P2362
[3]   TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES [J].
BARAKAT, RR ;
WONG, G ;
CURTIN, JP ;
VLAMIS, V ;
HOSKINS, WJ .
GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :164-168
[4]  
BOCCARDO F, 1981, ONCOLOGY, V38, P281, DOI 10.1159/000225571
[5]   TAMOXIFEN AND ENDOMETRIOSIS - CASE-REPORT [J].
BUCKLEY, CH .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (07) :645-646
[6]  
Cuenca RE, 1996, CANCER, V77, P2058, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2058::AID-CNCR14>3.3.CO
[7]  
2-V
[8]   MUCINOUS AND CLEAR-CELL ADENOCARCINOMAS OF THE ENDOMETRIUM IN PATIENTS RECEIVING ANTIESTROGENS (TAMOXIFEN) AND GESTAGENS [J].
DALLENBACHHELLWEG, G ;
HAHN, U .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1995, 14 (01) :7-15
[9]   ENDOMETRIAL LESIONS IN PATIENTS UNDERGOING TAMOXIFEN THERAPY [J].
DEMUYLDER, X ;
NEVEN, P ;
DESOMER, M ;
VANBELLE, Y ;
VANDERICK, G ;
DEMUYLDER, E .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1991, 36 (02) :127-130
[10]   RAPID GROWTH OF LEIOMYOMA IN PATIENT RECEIVING TAMOXIFEN [J].
DILTS, PV ;
HOPKINS, MP ;
CHANG, AE ;
CODY, RL .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (01) :167-168